Current issues in antiretroviral and psychiatric therapy for HIV-infected patients

AIDS Reader

Volumn 10, Issue 9, 2000, Pages 508-513

  Boyle, B A ^a   Goldenberg, D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Discontinuation; Efavirenz; Intermittent; Neuropsychiatric disorders; OI prophylaxis; Psychiatric factors; Sexual abuse; Viremia

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; NELFINAVIR; STAVUDINE;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; OPPORTUNISTIC INFECTION; PROPHYLAXIS; PSYCHIATRIC TREATMENT; REVIEW; SEXUAL ABUSE; VIREMIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; HIV INFECTIONS; HUMAN; MENTAL DISORDERS; OXAZINES; PNEUMONIA, PNEUMOCYSTIS CARINII; VIREMIA;

EID: 0033819289     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
2. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral treatment
3. Prevalence and predictive value of intermittent viremia in patients with viral suppression
4. The significance of low-level viremia in patients with previously 'undetectable' HIV-1 RNA levels
5. Can OI prophylaxis be stopped in patients responding to HAART?
6. Discontinuation of PCP prophylaxis is safe in HIV-infected patients alter inununological recovery with HAART: Results of the GESIDA 04/98 Study
7. A randomized, placebo-controlled trial of azithromycin prophylaxis for the prevention of Mycobacterium avium complex (MAC) in subjects with increases in CD4 cells on antiretroviral therapy
8. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
9. Can secondary Pneumocystis carinii pneumonia (PCP) prophylaxis be discontinued in HIV-infected patients treated with highly active antiretroviral therapy (HAART)
10. Discontinuation of secondary Pneumocystis carinii prophylaxis in HIV-1 infected patients after immunological recovery with HAART: Results of a prospective, randomized and multicentric clinical trial (the GESIDA 04/98 Study)